Business
Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen
Myrtelle Inc. ("Myrtelle" or the "Company"), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, today announced the official launch of commercial-stage manufacturing for its first-in-class oligotrophic recombinant adeno-associated virus (rAAV) gene therapy product, developed specifically for Canavan disease (CD). This landmark achievement propels Myrtelle's therapy closer to market and patients who urgently need it.
About this update from Charles River Laboratories International, Inc.
[{"type":"text","content":"Team prepares for commercialization bolstered by START Program and regulatory recognition ","length":89,"tagName":"p"},{"type":"text","content":"NEW YORK, July 8, 2025 /PRNewswire/ -- Myrtelle Inc. ("Myrtelle" or the "Company"), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, today announced the official launch of commercial-stage manufacturing for its first-in-class oligotrophic recombinant adeno-associated virus (rAAV) gene therapy product, developed specifically for Canavan disease (CD). This landmark achievement propels Myrtelle's therapy closer to market and patients who urgently need it.","length":551,"tagName":"p"},{"type":"image","alt":"A clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases. (PRNewsfoto/Myrtelle, Inc)","displaySize":"","headline":null,"caption":"A clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases. (PRNewsfoto/Myrtelle, Inc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":140,"url":"https://media.zenfs.com/en/prnewswire.com/64fdcaae10fee28b3e23197147e7fbaf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oye40kx4bWyOV_TpyM.QkA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI0NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/64fdcaae10fee28b3e23197147e7fbaf","width":400,"height":140}},"href":"https://mma.prnewswire.com/media/2375661/Myrtelle_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The manufacturing program is being executed in strategic partnership with two global leaders in gene therapy infrastructure: Charles River and Viralgen Vector Core (a subsidiary of AskBio Inc.). Together, the trio is setting a new standard in viral vector innovation, combining Myrtelle's proprietary science with Charles River's GMP plasmid manufacturing and analytical excellence at their CDMO center of excellence in Keele, UK, and Viralgen's cutting-edge GMP vector production at their world-class facility in San Sebastián, Spain.","length":547,"tagName":"p"},{"type":"text","content":""This is a transformative moment for Myrtelle and the entire Canavan disease community," said Adrian Stecyk, Chief Executive Offi...
More updates from Charles River Laboratories International, Inc.